Price T Rowe Associates Inc Elevation Oncology, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 16,841 shares of ELEV stock, worth $9,767. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,841
Previous 16,841
-0.0%
Holding current value
$9,767
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ELEV
# of Institutions
68Shares Held
45.4MCall Options Held
700Put Options Held
27.6K-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$3.48 Million0.19% of portfolio
-
Tang Capital Management LLC San Diego, CA4.76MShares$2.76 Million0.24% of portfolio
-
Goldman Sachs Group Inc New York, NY3.99MShares$2.31 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.53MShares$2.05 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.07MShares$1.78 Million0.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $13.5M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...